Vaxine Pty Ltd Is An Australian Biotechnology Company Based In Adelaidesouth Australiafounded In 2002It Specializes In The Development Of Vaccines And Immunotherapiesfocusing On Innovative Technologies To Tackle Global Health Challengesthe Company Has Made Significant Strides In Vaccine Developmentincluding The Creation Of The First Ai Designed Vaccine In 2019 And The First Approved Recombinant Spike Protein Covid 19 Vaccine In 2021 Vaxine S Covid 19 Vaccine Has Shown 78Efficacy Against Severe Delta Variant Disease And Has Been Approved For Use In The Middle Eastwith 8 Million Doses Delivered Through Its Partnercinnagen Corporationthe Company Also Utilizes Its Patented Advaxa C Adjuvant Platform To Enhance Vaccine Effectiveness And Is Actively Working On A Long Lasting Typhoid Fever Vaccine In Collaboration With Matrivax Incvaxine Maintains Strong Partnerships With Institutions Like The Us National Institutes Of Health And Is Committed To Translating Research Into Clinical Products While Prioritizing Accessibility And Safety In Its Vaccine Offerings
